1-4 of 4
Louise M. Kelly
Close
Sort by
Journal Articles

A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657

Jastinder Sohal, Vernon T. Phan, Philip V. Chan, Elizabeth M. Davis, Bhumi Patel, Louise M. Kelly, Tinya J. Abrams, Anne Marie O'Farrell, D. Gary Gilliland, Michelle M. Le Beau, Scott C. Kogan
Journal: Blood
Blood (2003) 101 (8): 3188–3197.
https://doi.org/10.1182/blood-2002-06-1800
Published: 2003
Journal Articles

The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3

Karsten Spiekermann, Ralf J. Dirschinger, Ruth Schwab, Ksenia Bagrintseva, Florian Faber, Christian Buske, Susanne Schnittger, Louise M. Kelly, D. Gary Gilliland, Wolfgang Hiddemann
Journal: Blood
Blood (2003) 101 (4): 1494–1504.
https://doi.org/10.1182/blood-2002-04-1045
Published: 2003
Journal Articles

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

Louise M. Kelly, Qing Liu, Jeffrey L. Kutok, Ifor R. Williams, Christina L. Boulton, D. Gary Gilliland
Journal: Blood
Blood (2002) 99 (1): 310–318.
https://doi.org/10.1182/blood.V99.1.310
Published: 2002
Journal Articles

Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophages

Nicole Faust, Florencio Varas, Louise M. Kelly, Susanne Heck, Thomas Graf
Journal: Blood
Blood (2000) 96 (2): 719–726.
https://doi.org/10.1182/blood.V96.2.719
Published: 2000